Simvastatin for Esophageal Cancer

(RESTAGE Trial)

This trial aims to determine if adding simvastatin, a common cholesterol medication, to standard cancer treatment can benefit people with esophageal cancer. Researchers hope it will enhance the cancer's response to treatment and extend the duration patients remain cancer-free. Participants will receive either the usual chemotherapy (with or without immunotherapy) or chemotherapy plus simvastatin. Individuals with esophageal or gastroesophageal junction cancer that may be surgically removable could be suitable for this trial. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

If you are currently taking cholesterol-lowering medications like statins, you cannot participate in the main trial but may join the observational arm. Also, if you are on certain medications that strongly interact with simvastatin, you may not be eligible for the trial.

Research has shown that simvastatin, a common cholesterol-lowering drug, is usually well-tolerated and linked to positive outcomes in patients with esophageal cancer. Studies have found that statins, like simvastatin, are associated with a lower risk of cancer and improved survival rates. For instance, individuals taking statins had a reduced chance of developing esophageal cancer. Additionally, statin use has been linked to lower death rates after a cancer diagnosis.

Unlike the standard treatment for esophageal cancer, which typically involves chemotherapy regimens like FLOT, simvastatin offers a fresh approach by incorporating a cholesterol-lowering medication into the treatment plan. Simvastatin is known for its ability to inhibit certain pathways that cancer cells use to grow and spread. Researchers are excited about this treatment because it targets cancer cells differently than traditional chemotherapy, potentially enhancing the effectiveness of existing treatments and improving outcomes for patients.

Research shows that simvastatin, a cholesterol-lowering drug, might help treat esophageal cancer. In this trial, one group will receive the standard neoadjuvant FLOT (or FLOT-D) treatment, while another group will receive the same treatment with added simvastatin. Studies have found that people taking statins, like simvastatin, have a lower risk of developing esophageal cancer. Additionally, those using statins tend to live longer when dealing with this type of cancer. Statin use is linked to a lower risk of death, resulting in better survival rates. This suggests that adding simvastatin to standard cancer treatments could slow cancer growth and improve survival chances.³⁴⁶⁷⁸